Upadacitinib (RINVOQ)
Janus kinase (JAK) inhibitor (selective immunosuppressant)
Upadacitinib (RINVOQ)
Forms and strengths
Form: TabletStrength: 15 mg, 30 mg, 45 mg
References
Indication
- Upadacitinib (RINVOQ) is used for moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate, as monotherapy or combined with methotrexate or other nonbiologic DMARDs.
- It is used for active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.
- It is used for active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults who have had an inadequate response to a biologic DMARD or when those therapies are inadvisable.
- It is used for giant cell arteritis in adults, combined with a tapering course of corticosteroids or as monotherapy after corticosteroids are stopped.
- It is used for refractory moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older weighing at least 40 kg who are not adequately controlled with, or cannot use, a systemic treatment.
- It is used for moderately to severely active ulcerative colitis and Crohn's disease in adults who have had an inadequate response, loss of response, or intolerance to conventional or biologic therapy.
- Upadacitinib should not be combined with other JAK inhibitors, immunomodulating biologics, or potent immunosuppressants such as azathioprine, 6-mercaptopurine, or cyclosporine.
Pregnancy
- Upadacitinib should not be used during pregnancy, as animal studies showed it is teratogenic, causing skeletal malformations in rats and cardiovascular malformations in rabbits.
- Increased pregnancy loss and decreased fetal body weight were also observed in animal studies.
- Women of reproductive potential should use effective contraception during treatment and for 4 weeks after the final dose.
- Patients who become pregnant while taking upadacitinib should be informed of the potential hazard to the fetus.
Breastfeeding
- It is not known whether upadacitinib passes into human breast milk, but animal studies found drug levels in milk approximately 30 times higher than in maternal plasma.
- A risk to breastfed infants cannot be excluded.
- Breastfeeding is not recommended during treatment and for 6 days (about 10 half-lives) after the last dose.
Geriatrics
- Caution should be used when treating patients 65 years of age and older, as there is a higher rate of adverse events, including serious infections, in this age group.
- Only the 15 mg once-daily dose is recommended for patients 65 years of age and older; the 30 mg dose is not recommended in this age group.
- There is limited data in patients 75 years of age and older.
Pediatrics
- RINVOQ is approved for adolescents 12 years of age and older weighing at least 40 kg for refractory moderate to severe atopic dermatitis.
- Safety and efficacy have not been established in adolescents weighing less than 40 kg or in children under 12 years of age with atopic dermatitis.
- Safety and efficacy have not been established in children or adolescents under 18 years of age for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Dosage & Administration
- For rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, the recommended dose is 15 mg once daily.
- For giant cell arteritis, the recommended dose is 15 mg once daily combined with a tapering course of corticosteroids, or as monotherapy after corticosteroids are stopped.
- For atopic dermatitis, the recommended starting dose is 15 mg once daily, which may be increased to 30 mg once daily if response is inadequate; discontinue if the 30 mg dose has not produced an adequate response after 16 weeks.
- For ulcerative colitis and Crohn's disease, induction treatment is 45 mg once daily for 8 weeks (ulcerative colitis) or 12 weeks (Crohn's disease), followed by a maintenance dose of 15 mg or 30 mg once daily based on disease severity and response.
- Treatment should be interrupted for a serious infection, an absolute neutrophil count under 1 x 10^9 cells/L, an absolute lymphocyte count under 0.5 x 10^9 cells/L, or hemoglobin under 80 g/L.
- RINVOQ should not be started in patients with severe hepatic impairment (Child-Pugh C); no dose adjustment is needed for mild or moderate hepatic impairment.
- For severe renal impairment, the dose is 15 mg once daily for most indications, or an induction dose of 30 mg with a maintenance dose of 15 mg for ulcerative colitis and Crohn's disease; no adjustment is needed for mild or moderate renal impairment.
- If a dose is missed and it is more than 10 hours before the next scheduled dose, take it as soon as possible; if less than 10 hours remain, skip the missed dose and resume the normal schedule the next day.
- Tablets should be swallowed whole and not split, crushed, or chewed.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Clinical trials tested upadacitinib at doses well above the usual therapeutic range without identifying a distinct overdose toxidrome; adverse effects were similar to those seen at normal doses.
- About 90% of a dose is cleared from the body within 24 hours, which limits how long any overdose effects would persist.
- Management is supportive: monitor the patient for signs and symptoms of adverse reactions and treat any that develop.
Common side effects
- Upper respiratory tract infection may occur.
- Nausea may occur.
- Cough or bronchitis may occur.
- Headache may occur.
- Back pain may occur.
- Fatigue may occur.
- Elevated creatine phosphokinase (CPK) may occur.
- Elevated liver enzymes (ALT/AST) may occur.
- Fever may occur.
- Elevated cholesterol may occur.
- Weight gain may occur.
- Acne may occur.
- Peripheral swelling (edema) may occur.
- Urinary tract infection may occur.
- Herpes simplex or oral candidiasis may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Serious infections, including pneumonia and cellulitis, can occur and may lead to hospitalization or death.
- Tuberculosis, including extrapulmonary disease, and invasive fungal or opportunistic infections can occur.
- Herpes zoster (shingles), including multidermatomal cases, occurs more often than with some other treatments, and is more common in patients of Asian descent.
- Hepatitis B virus reactivation has been reported, even in patients who previously appeared to have resolved infection.
- Lymphoma and other malignancies, including non-melanoma skin cancer and lung cancer, have been observed, with higher rates seen at the 30 mg dose.
- Blood clots, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred and have sometimes been fatal.
- Major adverse cardiovascular events, including non-fatal heart attack, have occurred more often in at-risk patients treated with a related JAK inhibitor.
- Gastrointestinal perforation has been reported, particularly in patients with diverticular disease or those taking NSAIDs, corticosteroids, or opioids.
- Significant drops in neutrophil count, lymphocyte count, or hemoglobin can occur and may require interrupting treatment.
- Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
- Semen discolouration (blue or green) has been reported, with unknown clinical significance.
- Seek urgent medical attention for signs of infection such as fever or chills, chest pain or sudden shortness of breath, leg swelling or pain, sudden new or worsening abdominal pain, or signs of a severe allergic reaction.
Use with caution
- Use with caution in patients with chronic or recurrent infections, or a history of serious or opportunistic infection.
- Use with caution in patients who have resided in or traveled to areas with endemic tuberculosis or fungal infections.
- Use with caution in current or past smokers and in patients with other cardiovascular or malignancy risk factors.
- Use with caution in patients at increased risk for blood clots, including those with obesity, prior clot history, or those using combined hormonal contraceptives.
- Use with caution in patients with a history of diverticular disease, diverticulitis, or those taking NSAIDs, corticosteroids, or opioids, due to the risk of gastrointestinal perforation.
- Use with caution in patients receiving medication for diabetes, since hypoglycemia has been reported with JAK inhibitors.
- Monitor lipid levels, as treatment is associated with increases in cholesterol; manage according to standard hyperlipidemia guidelines.
- Live or attenuated vaccines should not be given immediately before or during treatment; patients should be brought up to date on immunizations, including zoster vaccination, before starting treatment.
- Use with caution in patients of Asian descent, due to an increased risk of herpes zoster.
- Monitor creatine phosphokinase in patients who develop muscle weakness or pain, to check for rhabdomyolysis.
Contraindications
- Contraindicated in patients with known hypersensitivity to upadacitinib or to any ingredient in the formulation.
Drug interactions
- Strong CYP3A4 inhibitors, such as ketoconazole and clarithromycin, increase upadacitinib exposure; the 15 mg dose should be used with caution during chronic use of these inhibitors, and the 30 mg dose is not recommended, though dose reduction rules apply for ulcerative colitis and Crohn's disease induction.
- Strong CYP3A4 inducers, such as rifampin, decrease upadacitinib exposure and may reduce its effectiveness; concomitant use is not recommended.
- Grapefruit inhibits CYP3A-mediated metabolism, and RINVOQ should be used with caution if taken with grapefruit juice.
- Other potent immunosuppressants, including azathioprine, cyclosporine, and tacrolimus, other JAK inhibitors, and biologic DMARDs have not been studied in combination with RINVOQ and carry a risk of additive immunosuppression; concomitant use is not recommended.
- Upadacitinib does not significantly affect methotrexate, sensitive CYP1A2, CYP2D6, or CYP2C19 substrates, or ethinylestradiol and levonorgestrel, based on drug interaction studies.
- Upadacitinib modestly decreases exposure to sensitive CYP3A substrates such as midazolam, and to rosuvastatin and atorvastatin; no dose adjustment of these drugs is required based on study findings.
Food interactions
- RINVOQ can be taken with or without food; a high-fat, high-calorie meal increases absorption somewhat, but this does not require any change in how the tablet is taken.
Time of administration
- Take once daily at any time of day, with or without food, swallowing the tablet whole.
Storage
- Store at 2°C to 25°C, in the original bottle, with the desiccant canister in place to protect from moisture.
- Keep out of reach and sight of children.
Patient take-away
- RINVOQ (upadacitinib) is a once-daily oral JAK inhibitor used for several inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
- It increases the risk of serious infections, including tuberculosis and shingles; report fever, chills, or any new signs of infection promptly.
- Regular blood tests are needed to monitor blood counts, liver enzymes, and cholesterol during treatment.
- Effective contraception is required during treatment and for 4 weeks afterward, since RINVOQ can harm a developing fetus.
- Seek urgent medical attention for chest pain, sudden shortness of breath, leg swelling, signs of infection, or sudden severe abdominal pain.